Clinical trials with MTDQ )[6,6'-methylene-bis (2,2,4-trimethyl-1,2-dihydroquinoline)], an antioxidant with radiation sensitizing effect

V. Erdelyi, V. Bar, Z. Pollak, J. Fodor, J. Kralovánszky, I. Tóth, I. Hindy, S. Eckhardt

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Daily doses of 1320 mg MTDQ were administered orally to 7 patients for 100 successive days. Biological half-life and serum concentration measurements were performed. Function of vital organs as well as routine laboratory findings revealed that MTDQ did not induce any toxic changes. The effect of MTDQ on the radiosensitivity of hypoxic tumor cells was studied in a combined treatment modality including 12 patients. The action on tumor regression was found encouraging. It has been found remarkable, too, that due to the effect of MTDQ and radiotherapy some of the nonspecific and general symptoms (e.g. pruritus) also disappeared.

Original languageEnglish
Pages (from-to)198-200
Number of pages3
JournalStrahlentherapie
Volume156
Issue number3
Publication statusPublished - 1980

Fingerprint

Radiation-Sensitizing Agents
Antioxidants
Clinical Trials
Poisons
Radiation Tolerance
Pruritus
Half-Life
Neoplasms
Radiotherapy
6,6'-methylene bis(2,2,4-trimethyl-1,2-dihydroquinoline)
Serum

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this

Erdelyi, V., Bar, V., Pollak, Z., Fodor, J., Kralovánszky, J., Tóth, I., ... Eckhardt, S. (1980). Clinical trials with MTDQ )[6,6'-methylene-bis (2,2,4-trimethyl-1,2-dihydroquinoline)], an antioxidant with radiation sensitizing effect. Strahlentherapie, 156(3), 198-200.

Clinical trials with MTDQ )[6,6'-methylene-bis (2,2,4-trimethyl-1,2-dihydroquinoline)], an antioxidant with radiation sensitizing effect. / Erdelyi, V.; Bar, V.; Pollak, Z.; Fodor, J.; Kralovánszky, J.; Tóth, I.; Hindy, I.; Eckhardt, S.

In: Strahlentherapie, Vol. 156, No. 3, 1980, p. 198-200.

Research output: Contribution to journalArticle

Erdelyi, V, Bar, V, Pollak, Z, Fodor, J, Kralovánszky, J, Tóth, I, Hindy, I & Eckhardt, S 1980, 'Clinical trials with MTDQ )[6,6'-methylene-bis (2,2,4-trimethyl-1,2-dihydroquinoline)], an antioxidant with radiation sensitizing effect', Strahlentherapie, vol. 156, no. 3, pp. 198-200.
Erdelyi, V. ; Bar, V. ; Pollak, Z. ; Fodor, J. ; Kralovánszky, J. ; Tóth, I. ; Hindy, I. ; Eckhardt, S. / Clinical trials with MTDQ )[6,6'-methylene-bis (2,2,4-trimethyl-1,2-dihydroquinoline)], an antioxidant with radiation sensitizing effect. In: Strahlentherapie. 1980 ; Vol. 156, No. 3. pp. 198-200.
@article{7c73e3d3b6904cbdb9eb95c0ba092db1,
title = "Clinical trials with MTDQ )[6,6'-methylene-bis (2,2,4-trimethyl-1,2-dihydroquinoline)], an antioxidant with radiation sensitizing effect",
abstract = "Daily doses of 1320 mg MTDQ were administered orally to 7 patients for 100 successive days. Biological half-life and serum concentration measurements were performed. Function of vital organs as well as routine laboratory findings revealed that MTDQ did not induce any toxic changes. The effect of MTDQ on the radiosensitivity of hypoxic tumor cells was studied in a combined treatment modality including 12 patients. The action on tumor regression was found encouraging. It has been found remarkable, too, that due to the effect of MTDQ and radiotherapy some of the nonspecific and general symptoms (e.g. pruritus) also disappeared.",
author = "V. Erdelyi and V. Bar and Z. Pollak and J. Fodor and J. Kralov{\'a}nszky and I. T{\'o}th and I. Hindy and S. Eckhardt",
year = "1980",
language = "English",
volume = "156",
pages = "198--200",
journal = "Strahlentherapie und Onkologie",
issn = "0179-7158",
publisher = "Urban und Vogel",
number = "3",

}

TY - JOUR

T1 - Clinical trials with MTDQ )[6,6'-methylene-bis (2,2,4-trimethyl-1,2-dihydroquinoline)], an antioxidant with radiation sensitizing effect

AU - Erdelyi, V.

AU - Bar, V.

AU - Pollak, Z.

AU - Fodor, J.

AU - Kralovánszky, J.

AU - Tóth, I.

AU - Hindy, I.

AU - Eckhardt, S.

PY - 1980

Y1 - 1980

N2 - Daily doses of 1320 mg MTDQ were administered orally to 7 patients for 100 successive days. Biological half-life and serum concentration measurements were performed. Function of vital organs as well as routine laboratory findings revealed that MTDQ did not induce any toxic changes. The effect of MTDQ on the radiosensitivity of hypoxic tumor cells was studied in a combined treatment modality including 12 patients. The action on tumor regression was found encouraging. It has been found remarkable, too, that due to the effect of MTDQ and radiotherapy some of the nonspecific and general symptoms (e.g. pruritus) also disappeared.

AB - Daily doses of 1320 mg MTDQ were administered orally to 7 patients for 100 successive days. Biological half-life and serum concentration measurements were performed. Function of vital organs as well as routine laboratory findings revealed that MTDQ did not induce any toxic changes. The effect of MTDQ on the radiosensitivity of hypoxic tumor cells was studied in a combined treatment modality including 12 patients. The action on tumor regression was found encouraging. It has been found remarkable, too, that due to the effect of MTDQ and radiotherapy some of the nonspecific and general symptoms (e.g. pruritus) also disappeared.

UR - http://www.scopus.com/inward/record.url?scp=0018843458&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018843458&partnerID=8YFLogxK

M3 - Article

C2 - 6987780

AN - SCOPUS:0018843458

VL - 156

SP - 198

EP - 200

JO - Strahlentherapie und Onkologie

JF - Strahlentherapie und Onkologie

SN - 0179-7158

IS - 3

ER -